The Pharma Data

JANUARY 31, 2021

Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag© Technology. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Vaccination 52

Vaccination Vaccine Trials Protein 52

Delveinsight

FEBRUARY 25, 2021

The startup spun out of Georgia Tech in 2018 and is based on James Dahlman’s research, a professor in the university’s department of biomedical engineering and school of medicine. The researchers had previously discovered that when mouse tumors were treated with epigenetic drugs, there was an increase in T cells infiltrating cancer.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

JANUARY 10, 2023

Our catalog of over 6,500+ primary antibodies, 1,200+ secondary antibodies, and 50+ ELISA kits includes reagents for multiplex IF, flow cytometry, and more in fields including immunology, oncology, and neuroscience. Pillar 5: Protein OE/Epitope Tags. Antibody validation. Pillar 4: Biological Characteristics.

Antibody 52

Antibody Protein Reagent Scientist 52

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies.

Antibody 52

Antibody In-Vitro Trials Development 52

Rethinking Clinical Trials

MARCH 21, 2023

Goldberg Distinguished Professor and Chief of Oncology Physician-in-Chief, North Carolina Cancer Hospital Director, Cancer Outcomes Research Program University of North Carolina Slides Keywords Patient-reported outcomes, Oncology, Clinical Trials Key Points Symptoms are common in cancer care.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed. Know more about us on www.cytiva.com.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

pharmaphorum

OCTOBER 4, 2022

During the first stage of the initiative, more than 2,000 research papers were published, 49 clinical trials were carried out, and more than 30 patents were filed through the support of the US National Cancer Institute (NCI). Building a bank. Up in the clouds. The entire process takes place in the physician’s office, alongside a clinician.

Biobanking 104

Biobanking Clinical Trials Clinical Trials Trials 104

XTalks

DECEMBER 21, 2022

Additionally, advanced technologies like artificial intelligence (AI) and the adoption of digital tools in healthcare are allowing for improved treatments and care, and powerful research insights. The majority of gene therapies approved and under development are in the areas of oncology and rare disease. Gene Therapy Approvals.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

Delveinsight

DECEMBER 3, 2020

The researchers have been searching for ways to stop the ageing process for millennia; however, such methods remain obscure. The researchers concentrated on the “Yamanaka factors,” which are four transcription factors—Oct4, Sox2, Klf4 and c-Myc. Reversing vision loss by rolling back the ageing clock.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

XTalks

JANUARY 19, 2024

This biological variability adds complexity, but with that complexity comes the power to choose the targets, the tags and the payloads and select combinations appropriate to the patient to personalize that therapy. Radiotherapy and Oncology. International Journal of Radiation Oncology* Biology* Physics 76.3 2010): S108-S115.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

MARCH 22, 2023

Our webinars have become a key vendor-selection tool for decision-makers across the drug development pipeline — from discovery to commercialization — which is why all ten of the top ten contract research organizations (CROs) have worked with Xtalks. In 2015, Pfizer acquired Hospira. So, what was the reason for this decline?

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Rethinking Clinical Trials

JUNE 14, 2023

In any trial emulation, researchers encounter design emulation differences in addition to potential sources of bias. We’ve also launched a spin-off project called ENCORE which is focused on emulating oncology trials using oncology specialty EHR data. – What are you interested in on the analytic front regarding this topic?

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

Pharmaceutical Technology

MARCH 17, 2023

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. Between 2012 and 2022, the number of oncology risk sharing agreements increased massively by 498%.

Marketing 257

Marketing Drugs Research Analyst Manufacturing 257

The Pharma Data

MAY 4, 2021

Biosimilars, which grew 79% operationally to $530 million, primarily driven by recent oncology monoclonal antibody biosimilar launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the U.S.; Clinical and Research Developments. 47%. . . .

Vaccination 40

Vaccination Vaccine Production Sales 40